KIAA1549 inhibitors belong to a specific chemical class of compounds that are designed to target and modulate the activity of the KIAA1549 protein. KIAA1549, also known as C11orf95, is a relatively less studied protein with emerging importance in various cellular processes. These inhibitors are synthetic molecules or small molecules designed with the primary objective of interfering with the normal function or interactions of KIAA1549 within cells.
KIAA1549 inhibitors can vary widely, as they are specifically tailored to interact with the unique binding sites or regions of the KIAA1549 protein. These compounds may act by binding to KIAA1549 and altering its conformation, preventing its association with other proteins, or inhibiting its enzymatic activity if it possesses any. The development of KIAA1549 inhibitors can be driven by a variety of research objectives, such as understanding the physiological role of KIAA1549 in different cellular pathways or exploring its potential implications in disease states. Researchers employ various biochemical and biophysical techniques to validate the inhibitory activity of these compounds, often involving cell-based assays, protein-protein interaction studies, or structural biology approaches. Overall, KIAA1549 inhibitors represent a valuable tool in the scientific toolkit for unraveling the functional significance of this protein and its potential role in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
This is a small molecule that inhibits BRAFV600E and other BRAF mutants but not wild-type BRAF. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
Dabrafenib selectively inhibits BRAF mutations, including BRAFV600E. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor that works downstream of BRAF in the MAPK pathway. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib selectively inhibits MEK1 and MEK2 downstream of BRAF. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF inhibitor that also targets VEGFR and PDGFR. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Targets BRAFV600E as well as other mutated forms of BRAF. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
A potent and selective inhibitor of MEK1/2, affecting the MAPK/ERK pathway. | ||||||
Ulixertinib | 869886-67-9 | sc-507296 | 10 mg | $176.00 | ||
Targets ERK1/2 kinases in the MAPK pathway. | ||||||